ABSTRACT NUMBER: ESOC2026A2058 DIRECT ORAL ANTICOAGULANTS IN PEDIATRIC CONGENITAL AND ACQUIRED HEART DISEASE: IMPLICATIONS FOR STROKE PREVENTION – A SYSTEMATIC REVIEW AND META-ANALYSIS
Mohamed Hamouda Elkasaby, Mohamed Sherif Ali Ahmed, Noha Elmahdi, Mahmoud Balata · 2026
Read ABSTRACT NUMBER: ESOC2026A2058 DIRECT ORAL ANTICOAGULANTS IN PEDIATRIC CONGENITAL AND ACQUIRED HEART DISEASE: IMPLICATIONS FOR STROKE PREVENTION – A SYSTEMATIC REVIEW AND META-ANALYSIS by Mohamed Hamouda Elkasaby, Mohamed Sherif Ali Ahmed, Noha Elmahdi, Mahmoud Balata (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146391.txt.
Description
Mohamed Hamouda Elkasaby and co-authors pool trial evidence on direct oral blood thinners for children with congenital or acquired heart disease, a group at raised risk of clots and stroke. Standard thinners need injections or close monitoring, which is hard for children. The newer oral drugs are easier, but their role in these patients was unclear.
Four trials with over seven hundred children were combined. The oral drugs cut overall clotting events by more than half compared with standard care. Strokes were rare and occurred only in the control groups. Major bleeding did not differ significantly between groups. The authors support adding these drugs to stroke prevention strategies for high-risk children with heart disease.
Catalog record
| CREATOR | Mohamed Hamouda Elkasaby, Mohamed Sherif Ali Ahmed, Noha Elmahdi, Mahmoud Balata |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |